Literature DB >> 9025158

From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera.

S M Fruchtman1, K Mack, M E Kaplan, P Peterson, P D Berk, L R Wasserman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9025158

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  40 in total

1.  Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2014-10

2.  Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2015-03

Review 3.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 4.  Current applications of therapeutic phlebotomy.

Authors:  Tarek Bou Assi; Elizabeth Baz
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

Review 5.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

6.  Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Authors:  Srdan Verstovsek; Alessandro M Vannucchi; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Keita Kirito; Carlos Besses; Masayuki Hino; Beatriz Moiraghi; Carole B Miller; Mario Cazzola; Vittorio Rosti; Igor Blau; Ruben Mesa; Mark M Jones; Huiling Zhen; Jingjin Li; Nathalie Francillard; Dany Habr; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2016-04-21       Impact factor: 9.941

7.  Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials.

Authors:  John Mascarenhas; Ruben Mesa; Josef Prchal; Ronald Hoffman
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

Review 8.  Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.

Authors:  Bing Li; John O Mascarenhas; Raajit K Rampal
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 9.  Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.

Authors:  Brady L Stein; Stephen T Oh; Dmitriy Berenzon; Gabriela S Hobbs; Marina Kremyanskaya; Raajit K Rampal; Camille N Abboud; Kenneth Adler; Mark L Heaney; Elias J Jabbour; Rami S Komrokji; Alison R Moliterno; Ellen K Ritchie; Lawrence Rice; John Mascarenhas; Ronald Hoffman
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

Review 10.  The treatment of polycythaemia vera: an update in the JAK2 era.

Authors:  G Finazzi; T Barbui
Journal:  Intern Emerg Med       Date:  2007-03-31       Impact factor: 3.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.